Altimmune ALT Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept alt:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's accrued expenses and other current liabilities?
- Altimmune (ALT) reported accrued expenses and other current liabilities of $9.79M in Q1 2026.
- How has Altimmune's accrued expenses and other current liabilities changed year-over-year?
- Altimmune's accrued expenses and other current liabilities increased by 12.3% year-over-year, from $8.72M to $9.79M.
- What is the long-term trend for Altimmune's accrued expenses and other current liabilities?
- Over 5 years (2020 to 2025), Altimmune's accrued expenses and other current liabilities has grown at a 1.5% compound annual growth rate (CAGR), from $11.41M to $12.28M.
- What does accrued expenses and other current liabilities mean?
- This represents short-term obligations for goods and services received but not yet invoiced or paid, including accrued compensation, professional fees, and clinical trial costs. It serves as a measure of the company's immediate operational commitments and unpaid liabilities due within one year. Monitoring this balance helps investors assess the company's short-term cash outflow requirements and the accuracy of its expense recognition.